TrialBMC medicine2024

Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial.

Haixia Fu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.